Similar articles

• Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin).

  Baumgärtel MW, Eichler P, Glöckner WM, Ranze O, Greinacher A. Baumgärtel MW, et al. Eur J Haematol. 2000 Aug;65(2):148-9. doi: 10.1034/j.1600-0609.2000.9l225.x. Eur J Haematol. 2000. PMID: 10966178 No abstract available.
• Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin.

  Shapiro M, Cohen J, Inbal A, Singer P. Shapiro M, et al. Isr Med Assoc J. 2009 Mar;11(3):188-90. Isr Med Assoc J. 2009. PMID: 19544713 No abstract available.
• Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.

  Grassegger A, Fritsch P, Reider N. Grassegger A, et al. Dermatol Surg. 2001 Jan;27(1):47-52. Dermatol Surg. 2001. PMID: 11231243
• Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

  Lubenow N, Greinacher A. Lubenow N, et al. J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:47-57. doi: 10.1023/a:1027333320023. J Thromb Thrombolysis. 2000. PMID: 11155194 Review. No abstract available.
• [Delayed hypersensitivity to heparins and heparinoids].

  Nicolie B, Bonneau JC, Le Sellin J, Gay G, Leclere JM, Drouet M. Nicolie B, et al. Allerg Immunol (Paris). 2002 Feb;34(2):47-50. Allerg Immunol (Paris). 2002. PMID: 11933754 Review. French.